Walleye Trading’s Cardiff Oncology CRDF Stock Holding History

Walleye Trading’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,300	Closed	-$22K	–	5023
2022 Q3	$22K	Sell	14,300 -49,800	-78%	-$120K	﹤0.01%	4410
2022 Q2	$141K	Buy	+64,100	New	+$107K	﹤0.01%	3948

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Walleye Trading's CRDF Position: Q2 2022 in Review

Walleye Trading sold out of Cardiff Oncology (CRDF) in Q2 2022, closing a stake of 45,154 shares — an estimated $75.6K sold.

Walleye Trading first reported a position in CRDF in Q2 2015 and held it in 3 quarters. The position peaked at $112K in Q1 2022. 67 funds tracked by Wall St. Rank hold CRDF as of Q2 2022.

Walleye Trading reported no remaining Cardiff Oncology position as of Q2 2022 after selling out during the quarter.
Walleye Trading sold 45,154 Cardiff Oncology shares in Q2 2022, an estimated $75.6K.
Walleye Trading first reported a position in Cardiff Oncology in Q2 2015 and held it in 3 quarters.
Walleye Trading's Cardiff Oncology position peaked at $112K in Q1 2022.
67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2022.

Based on Walleye Trading's 13F filing for Q2 2022, filed 8 Aug 2022.